US 11,685,713 B2
Small molecule SHC blockers used for treating liver disease and metabolic disease
Gino Cortopassi, Davis, CA (US); Alexey Tomilov, Davis, CA (US); and Dmytro Kovalskyy, San Antonio, TX (US)
Assigned to Buto Corporation, Davis, CA (US)
Filed by Buto Corporation, Davis, CA (US)
Filed on Jun. 27, 2022, as Appl. No. 17/809,158.
Application 17/809,158 is a continuation of application No. PCT/US2020/067511, filed on Dec. 30, 2020.
Claims priority of provisional application 62/955,057, filed on Dec. 30, 2019.
Prior Publication US 2023/0002317 A1, Jan. 5, 2023
Int. Cl. C07D 207/20 (2006.01); C07D 413/12 (2006.01)
CPC C07D 207/20 (2013.01) [C07D 413/12 (2013.01)] 16 Claims
 
1. A compound of Formula II:

OG Complex Work Unit Chemistry
wherein,
Ring M, J, J′, q, and w form

OG Complex Work Unit Chemistry
wherein J′ is naphthalenyl, w is 1, and q is 0;
P is a bond;
D is absent;
G is C═O;
R5 is selected from the group consisting of hydrogen, hydroxyl, and linear or branched C1-C3 alkyl;
R6 is selected from the group consisting of alkyl-S(O)m, haloalkyl-S(O)m, alkenyl-S(O)m, alkynyl-S(O)m, cycloalkylalkyl-S(O)m, aryl-S(O)m, arylalkyl-S(O)m, heterocycloalkyl-S(O)m, and heteroaryl-S(O)m, wherein S in —S(O)m is optionally substituted 1 to 3 times, in each instance, with arylalkyl, aryl, heterocyclo, or heteroaryl; and
m is 1, 2 or 3;
or a pharmaceutically acceptable salt thereof.